Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Jan 1, 2009 (Vol. 29, No. 1)

Stem Cells Continue March Toward Clinic

New Methodologies and Technologies Abound in Both Quality and Quantity

  • Click Image To Enlarge +
    Using Harvest Technologies’ BMAC system, bone marrow aspirate concentrate (BMAC) can be prepared at a patient’s bedside from a small volume of bone marrow that is percutaneously aspirated from the patient’s hip.

    Stem cell therapy holds great promise for various diseases. In fact, in what many are hailing as a medical milestone, European researchers have successfully transplanted a trachea built from a patient’s own stem cells to replace a failing airway damaged by tuberculosis, according to a recent article in The Lancet.

    The team stripped a donor trachea of all its cells and used the remaining collagen as a scaffold that was seeded with the patient’s stem cells. Four days after surgery, the engineered windpipe was almost indistinguishable from normal bronchi; four months post-surgery, the patient shows no signs of rejection and is enjoying a normal quality of life.

    This success may help future stem cell applications overcome some of the current challenges, which speakers at the “Stem Cell Summit” to be held next month, talked to GEN about in advance of the meeting. The scientists interviewed for this article were especially concerned about regulatory issues—is it a device, biologic, or both; financial matters—it’s an early field and federal funding for embryonic stem cell research has been put on hold; quality and quantity assurance of stem cells to enhance patient outcomes; and understanding their mechanism of action.

    Despite the challenges, however, a recent BBC Research market report (July 2008) estimates the U.S. market for stem cell technology is expected to increase from $112 million in 2007 to $423 million in 2012.

    Since the 1970s, Stuart Williams, Ph.D, CSO at Tissue Genesis, has been experimenting with isolating cells from fat to test their potential use in building blood vessels. The resulting mix of adult stem cells has regenerative qualities. “I started using these cells in lab experiments and learned how to isolate them. I realized this type of therapy needed to be automated in a totally closed system.”

    This conclusion led to the development of the company’s TG1 1000 cell isolation system. The compact desktop unit provides isolated cells in about an hour, according to the company, and accepts fat tissue from the same device used for tissue harvesting.

    Dr. Williams explains that the most critical component of the process is the company’s enzyme mixture to digest tissue and keep the cells viable. Initial efforts involved using the cells to reline artificial blood vessels. His group took Gortex-like tubing commonly used in vascular procedures and lined the inner surface with the patient’s own cells derived from fat, which re-created the natural blood vessel lining rapidly after the implant.

    “We only need about 30 grams of fat for vascular grafts. Each gram provides about a million therapeutic cells and is consistent from patient to patient,” explains Dr. Williams. The stromal cells take cues from the extracellular matrix proteins they are surrounded with. So if they are removed from fat and placed in a new environment, like the heart, they will take their cues from heart tissue. “You can put them in a 2-D or 3-D environment and the matrix will have a dramatic effect on their phenotype and function.”

    The company has set up a consortium that explores these cells for orthopedic (spinal fusions), cardiac (congestive heart failure, myocardial infarction), and inflammation (currently for veterinarian use only) applications.

    Dr. Williams says that they are now working with the FDA to gain approval of the device for specific therapeutic applications. “The device itself is just a complex centrifuge digestion system. What you use the cells for will dictate within FDA regulations whether it will go through an IDE process or an IND process and whether it will be registered as a biologic or a combination product.”

  • Cord Blood

    Isolating cells without touching their surface is a way to avoid creating molecular activity or reactions. This is a key concept behind BioE ’s cord blood closed-bag processing system, PrepaCyte®-CB. “We wanted to optimize negative selection—get rid of unwanted cells—to obtain a highly purified population or group of populations, without touching the cells,” says Michael Haider, president and CEO.

    The process is biological rather than mechanical. “We use mother nature and various materials depending on the cell population we’re trying to remove.” Only a small amount of biologic is required, and simple gravity is used for cell isolation. Since the dynamic range of the biologic is broad, exact mixtures are not required, Haider adds.

    Approximately 98.5% of all red blood cells are removed in about 30 minutes, leaving nucleated and stem cells. Total nucleated cell count is the industry-standard measurement for cord blood samples and directly correlates to patient outcomes in transplants. Few cord blood samples make the cut—only about 25% are suitable for banking; 75% are thrown out due to low volume or cell count.

    Currently, PrepaCyte-CB is a class II device, which allows sales to institutions regulated by an IND. Dr. Haider says the company’s main focus over the next six months is to obtain FDA 510(k) approval, which will open up global markets and allow sales to private cord blood banks.

    “We believe this is setting a new pathway and enablement where the biologic is an enclosed system at the time of manufacture and all the work occurs by the biological fluid. The FDA is moving toward tighter regulations. The industry needs to continue to improve on the quality of the material that’s transplanted into the patient —this is usually a life or death issue,” Dr. Haider adds.

  • Services for Community

    Progenitor Cell Therapy has expanded its services to include consulting, product development, cGMP-compliant contract cell manufacturing, and creating clinical trial products. The company recently received AABB accreditation in cord blood activities—processing, storage, and distribution.

    It has worked with a wide range of cell products other than stem cells including T cells, skin products, mesenchymal stem cells, neural products for CNS disorders, and protein products for cancer. Robert Preti, Ph.D., company president and CSO, reports that one of the greatest challenges of bringing stem cells into the clinic is “converting great science into technical feasibility as an industry.”

    Additional challenges for this industry are many, he adds. Regulatory framework is less problematic than a few years ago because the FDA has been working with industry so companies now understand the basic framework around cell therapies. Clinical challenges are still complex—how do the cells work, what are they supposed to do once infused/transplanted, and will the cells be economically feasible?

    Financing, especially now, is a huge concern. “There’s a certain amount of investor wariness that has taken place. It’s more difficult now to get funding to advance these therapies and the lack of federal funding for embryonic stem cell research has put a hold on that field,” states Dr. Preti. Manufacturing challenges arise from characterization of the product. “If you can figure out mechanism of action—how to characterize a cell product that typically is not a homogenous group of cells?—how do you define it? and what is the potency measurement?” He says that safety is not an issue with adult stem cells, but the biggest problem is identity of the product and potency; how do they work? and do they work?

    “Since we don’t have the ability to fully characterize the cell product itself, we are forced to view the process as the product, and when we do that, we have to define the process very carefully,” Dr. Preti states. This points to other challenges like logistics—getting the product delivered to the applications site and setting up facilities. “When you are dealing with stem cells, you are talking about cures versus palliative treatment. That’s a lofty goal. And well worth the effort.”

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »